Rafael Gómez Navarro
Research Subjects
Research Interests
Rafael Gómez Navarro has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Paloma González García
2 shared publicationsSantiago Valdearcos Enguídanos
2 shared publicationsCarlos Martín Hernández
1 shared publication- Carlos Martín-Hernández
Hospital Universitario Miguel Servet - IIS Aragón, Zaragoza, Spain
1 shared publication Daniel Escribano Pardo
Aragon Hlth Serv, Zaragoza, Spain
1 shared publicationElena Asso Otal
Aragon Hlth Serv, Zaragoza, Spain
1 shared publication
Latest Publications
- 10 July 2024
- Published by Elsevier in Primary Care Diabetes
- Vol. 18 (5) , 555-560
Prevalence and characteristics of chronic kidney disease in people with type 2 diabetes mellitus in the Autonomous Community of Aragon
- 10 July 2024
- Published by Elsevier in Primary Care Diabetes
- Vol. 18 (5) , 555-560
Prevalence and characteristics of chronic kidney disease in people with type 2 diabetes mellitus in the Autonomous Community of Aragon
- 30 December 2017
- Published by e-Medfarma 2020, S.L. in Medicina General y de Familia
- Vol. 6 (6) , 252-257
Influencia de los fenómenos meteorológicos en la incidencia de fracturas de cadera en los varones de Teruel
Objetivo. Evaluar la influencia de la estacionalidad y otros factores meteorológicos en la incidencia y tipos de la fractura de cadera por fragilidad en varones > 65 años en Teruel capital.
- 30 December 2017
- Published by e-Medfarma 2020, S.L. in Medicina General y de Familia
- Vol. 6 (6) , 252-257
Influencia de los fenómenos meteorológicos en la incidencia de fracturas de cadera en los varones de Teruel
Objetivo. Evaluar la influencia de la estacionalidad y otros factores meteorológicos en la incidencia y tipos de la fractura de cadera por fragilidad en varones > 65 años en Teruel capital.
- Open Access
- 2 January 2017
- Vol. 91
[Primary and Secondary Prevention of Hip Fragility Fracture in Teruel Health Sector, Aragon, Spain].
Osteoporosis should be prevented, diagnosed and treated, preferably before the fragility fracture occurs. The objective was to analyze primary and secondary interventions carried out in individuals diagnosed with femur fragility fracture at Teruel in 2014. Descriptive retrospective study. Variables assessed were sex, age, main health district, place of residence, basal functional situation, diagnosis on osteoporosis, hip or vertebral fracture, loss of height, use of FRAX tool, treatment on discharge, survival and cause of exitus. Student's t-test and ANOVA were used for quantitative variables by categories and regression for linear relationships. 148 patients were included. 123 were women median age was 87 years, 123 (76,4%) were women, 27,4% of the patients were totally or severely dependent for activities of daily living and 33% of them were living in a nursing home. There was a previous history of hip fracture in 10,1%, and one or more vertebral fractures in 10,1%. FRAX® tool was not used in any case. 12,2% of patients had been treated with calcium prior to fracture, 11,5% with vitamin D, and 6,8% of them with antiosteoporotic drugs. Only 52,7% were treated for secondary prevention after discharge. At the end of follow-up, 25,7% of hip fractured patients had died. Median survivorship of deceased patients was 64,5 days. 42,3% of exitus were caused by cardiovascular disease, 23,1% by infection and 11,5% by neoplasms. Primary pharmacologic prevention and assessment of osteoporosis or risk of fracture are unfrequent in our health district.. Although pharmacologic treatment is prescribed more frequently in Teruel than in other areas after a hip or vertebral fracture, additional measures should be taken in order to improve fragility fracture prevention.
- 2 January 2017
- Vol. 91
Open Access[Primary and Secondary Prevention of Hip Fragility Fracture in Teruel Health Sector, Aragon, Spain].
Osteoporosis should be prevented, diagnosed and treated, preferably before the fragility fracture occurs. The objective was to analyze primary and secondary interventions carried out in individuals diagnosed with femur fragility fracture at Teruel in 2014. Descriptive retrospective study. Variables assessed were sex, age, main health district, place of residence, basal functional situation, diagnosis on osteoporosis, hip or vertebral fracture, loss of height, use of FRAX tool, treatment on discharge, survival and cause of exitus. Student's t-test and ANOVA were used for quantitative variables by categories and regression for linear relationships. 148 patients were included. 123 were women median age was 87 years, 123 (76,4%) were women, 27,4% of the patients were totally or severely dependent for activities of daily living and 33% of them were living in a nursing home. There was a previous history of hip fracture in 10,1%, and one or more vertebral fractures in 10,1%. FRAX® tool was not used in any case. 12,2% of patients had been treated with calcium prior to fracture, 11,5% with vitamin D, and 6,8% of them with antiosteoporotic drugs. Only 52,7% were treated for secondary prevention after discharge. At the end of follow-up, 25,7% of hip fractured patients had died. Median survivorship of deceased patients was 64,5 days. 42,3% of exitus were caused by cardiovascular disease, 23,1% by infection and 11,5% by neoplasms. Primary pharmacologic prevention and assessment of osteoporosis or risk of fracture are unfrequent in our health district.. Although pharmacologic treatment is prescribed more frequently in Teruel than in other areas after a hip or vertebral fracture, additional measures should be taken in order to improve fragility fracture prevention.